<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840239</url>
  </required_header>
  <id_info>
    <org_study_id>2018-FXY-149</org_study_id>
    <secondary_id>5010-2018-04</secondary_id>
    <nct_id>NCT03840239</nct_id>
  </id_info>
  <brief_title>TNT Versus Conventional CRT to Increase the Sphincter Preservation Rate for Distal LARC</brief_title>
  <acronym>TESS</acronym>
  <official_title>Total Neoadjuvant Treatment vErsus Standand Chemoradiation to Increase the Sphincter Preservation Rate for Distal Locally Advanced Rectal Cancer (TESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TNT versus. conventional CRT for distal locally advanced rectal cancer (TESS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment of rectal cancer is neoadjuvant capecitabine chemotherapy with
      radiotherapy, followed by total mesorectal excision.

      A new concept suggests organ preservation as an alternative to rectal excision in good
      responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase
      quality of life.

      The rational is the fact that 15%-20% of patients have sterilized tumours after
      chemoradiotherpay for locally advanced rectal cancer. As compared to capecitabine alone,
      oxaliplatin and more intensified chemotherapy have been shown to increase tumor regression in
      the neoadjuvant chemoradiation setting. Meanwhile, prolong of time interval from the end of
      radiotherapy to assessment of tumor response could further increase pathologic complete
      response rate and complete clinical response rate.

      The objective of this trial is to increase the proportion of sphincter preservation rate for
      distal rectal cancer patients by optimizing tumour response. The investigators expect to
      increase chance of organ preservation rate by using total neoadjuvant treatment regimen as
      compared to conventional chemoradiotherapy alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of sphincter preservation (absence of stoma)</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>Number of patients with sphincter preservation and absence of stoma at 1.5 year after diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of sphincter preservation strategy</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>Number of patients with sphincter preservation through Watch and wait strategy, or local excision, or intersphincter resection, or low anterior resection, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pathological complete response and tumor regression grade distribution</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>Rate of pathological complete response and tumor regression grade distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>Within the first course of anti-tumor treatment</time_frame>
    <description>Acute toxicity according to CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical complications</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>Rate of surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term anal function</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>Long-term anal function according to Wexner Continence Grading Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term toxicity grading</measure>
    <time_frame>3 year after the end of the first course of anti-tumor treatment</time_frame>
    <description>Long-term toxicity grading according to CTCAE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECOG standard score</measure>
    <time_frame>1.5 year after diagnosis</time_frame>
    <description>ECOG standard score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year disease free survival</measure>
    <time_frame>3 year after the end of the first course of anti-tumor treatment</time_frame>
    <description>3 year disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 year overall survival</measure>
    <time_frame>5 year after the end of the first course of anti-tumor treatment</time_frame>
    <description>5 year overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Rectal Cancer Stage II</condition>
  <condition>Rectal Cancer Stage III</condition>
  <condition>Chemoradiation</condition>
  <arm_group>
    <arm_group_label>TNT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.
External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Neoadjuvant chemotherapy, Capecitabine, 5 weeks; adjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles.
External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Oxaliplatin</intervention_name>
    <description>Drug: Capecitabine, Oxaliplatin</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>TNT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy</intervention_name>
    <description>External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>TNT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>TNT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watch and wait strategy</intervention_name>
    <description>Watch and wait strategy recommendation and discussion for cCR patients</description>
    <arm_group_label>CRT arm</arm_group_label>
    <arm_group_label>TNT arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rectal adenocarcinoma

          -  cT3-4aNany or cTanyN+

          -  Location ≤5 cm from the anal verge

          -  No distant metastasis

          -  No gastrointestinal obstruction or relieved obstruction

          -  No previous surgery of the rectum, no previous chemotherapy, no previous pelvic
             radiation, no previous biotherapy

          -  ECOG 0-1

          -  Expected survival length ≥ 2 years

          -  Age 18-70

          -  Sufficient bone marrow, kidney and liver function

          -  Effective contraception during the study

          -  Patient and doctor have signed informed consent

        Exclusion Criteria:

          -  Distant metastasis

          -  Chronic intestinal inflammation and/or bowel obstruction

          -  Contra indication for chemotherapy and/or radiotherapy

          -  Previous pelvic radiotherapy or chemotherapy

          -  Severe renal, hepatic insufficiency (serum creatinine&lt;30ml/min)

          -  Peripheral neuropathy &gt; grade 1

          -  Pregnant or breast-feeding woman

          -  Certain or suspicious allergy to research drug

          -  Cachexia, organ dysfunction

          -  Active severe infection

          -  Multiple primary cancers

          -  Epileptic seizures

          -  Malignant history within 5 years, except cervical carcinoma in situ or cutaneous basal
             cell carcinoma

          -  Severe arrhythmia, cardiac dysfunction (NYHA grade III or IV )

          -  Uncontollable severe hypertesion

          -  Persons deprived of liberty or under guardianship

          -  Impossibility for compliance to follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WeiWei Xiao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WeiWei Xiao</last_name>
    <phone>8613710390520</phone>
    <phone_ext>8613710390520</phone_ext>
    <email>xiaoww@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WeiWei Xiao</last_name>
      <phone>8613710390520</phone>
      <phone_ext>8613710390520</phone_ext>
      <email>xiaoww@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>WeiWei Xiao</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>total neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

